Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 43 NovoRapidⓇ market share tMU tMU Novo Nordisk's modern insulins continue solid performance within their respective segments Fast-acting insulin Segment volume Long-acting insulin Segment volume LevemirⓇ market share Premix insulin Segment volume NovoMixⓇ market share tMU 200 100% 200 100% 200 100% CAGR¹ volume: 5.1% CAGR¹ volume: 2.2% MI penetration: 77.4% MI penetration: 47.1% CAGR¹ volume: 6.1% MI penetration: 81.3% 160 80% 160 80% 160 80% 120 60% 120 60% 120 60% 80 40% 80 40% 80 40 20% 40- 20% 40 40% 20% 0% 0 0% 0 Aug 2011 Aug 2016 Aug 2011 Aug 2016 Aug 2011 0% Aug 2016 1 CAGR for 5-year period Note: Modern insulin (MI) penetration is of total segment, ie including animal and human insulin; NG: new-generation; Data is sensitive to changes in IMS data collection and reporting methodology Source: IMS Monthly MAT August, 2016 volume figures changing diabetes® novo nordisk

View entire presentation